Arrowhead Pharmaceuticals: Morgan Stanley upgrades to Overweight with target of $100 - Focus on price increase above resistance line

Arrowhead Pharmaceuticals (ARWR) is developing medications based on RNA interference (RNAi). This technology aims to "silence" disease-causing genes before harmful proteins are ever produced. This is considered one of the most innovative approaches in modern biotechnology. The market for cardiovascular and metabolic diseases is enormous. If Arrowhead can prove that their drug safely and effectively lowers severe hypertriglyceridemia, the drug could become a blockbuster. Morgan Stanley believes that this potential success is not yet fully priced...